粒细胞集落刺激因子（granulocyte colony stimulating factor，G-CSF）也称为集落刺激因子 3（colony stimulating factor 3，CSF3），是一种含有 174 个 氨基酸的糖蛋白（19.6 ...

化疗导致的中性粒细胞减少（CIN)和粒细胞减少性发热（FN)会增加侵袭性感染的发生风险，可能会引起治疗费用的增加、抗生素的使用、住院时间的延长、化学药物的减量或延迟，严重者可导致感染性休克、脓毒综合征等危及生命的并发症，甚至导致患者死亡。一、中性粒细 ...

CSF oligoclonal bands is a test ordered by physicians when serious health concerns related to your central nervous system arise. Here’s what you need to know about it. If your physician suspects ...

Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was ...

Recombinant granulocyte-CSF (G-CSF) and granulocyte–macrophage-CSF (GM-CSF) have now been used to increase dangerously low white blood cell levels in many millions of cancer patients following ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the ...

The US Program leads with the principle of racial justice and equity as a fundamental human right providing the foundational, over-arching, and unifying theme for all our work. Our strategic ...

What are the latest Once Human codes? There are times in all of our gaming lives when we need a little bit of help. Call it a handout, call it a freebie, call it whatever you like, but receiving a ...

Our lead program, molgramostim inhalation solution, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar ...

The sale of Steward Health Care’s physician network to another private equity-backed company carries “limited potential for negative impacts on spending and market dynamics,” state health ...

Nov. 8, 2024 — Researchers identify a key pathway leading to neurodegeneration in early stages of ALS, hinting at the potential for short-circuiting the progression of the fatal disease if ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third ...